碳青霉烯类药物致血小板不良反应分析及相关文献回顾

doi:10.5246/jcps.2023.10.067

中国药学(英文版) ›› 2023, Vol. 32 ›› Issue (10): 835-841.DOI: 10.5246/jcps.2023.10.067

碳青霉烯类药物致血小板不良反应分析及相关文献回顾

常馨予, 韩丽娟, 刘洋, 范峥, 吴剑坤^*()

首都医科大学附属北京中医医院药学部, 北京 100038

收稿日期:2023-04-26 修回日期:2023-06-11 接受日期:2023-06-26 出版日期:2023-11-04 发布日期:2023-11-04
通讯作者: 吴剑坤
作者简介:
+ Tel.: +86-10-87907321, E-mail: changxinyu@bjzhongyi.com

Analysis of adverse drug reactions caused by carbapenems and review of related literature

Xinyu Chang, Lijuan Han, Yang Liu, Zheng Fan, Jiankun Wu^*()

Department of Pharmacy, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100038, China

Received:2023-04-26 Revised:2023-06-11 Accepted:2023-06-26 Online:2023-11-04 Published:2023-11-04
Contact: Jiankun Wu

摘要/Abstract

摘要：

本研究通过搜集临床应用碳青霉烯类药物引起药物性血小板异常不良反应的文献, 分析碳青霉烯类药物引起药物性血小板异常病例及其临床特点, 为碳青霉烯类药物临床安全用药提供参考。通过检索PubMed、Medline数据库、中国学术期刊全文数据库(CNKI)和维普中文科技期刊数据库, 搜集碳青霉烯类药物亚胺培南和美罗培南致血小板异常的不良反应个例报道, 并对患者基础情况(如性别和年龄)以及基础疾病、合并用药以及预后情况进行统计分析。共搜集到临床应用3例使用亚胺培南和17例使用美罗培南后发生了血小板异常的不良反应病例报道。统计发现20例不良反应中碳青霉烯类药物导致血小板升高的11例, 导致血小板降低的9例。20例患者在停药后4–18天内转归, 不良反应类型均为严重药品不良反应。碳青霉烯药物引起血小板异常的不良反应报道较少, 但后果较严重, 临床应用应特别注意碳青霉烯类药物血液方面的不良反应, 早期及时监测并及时给予对症处理。

关键词: 碳青霉烯类药物, 血小板减少, 药品不良反应, 文献分析

Abstract:

This study aimed to review the literature on adverse drug reactions (ADRs) caused by the clinical use of carbapenems and their effects on platelet abnormalities. We also analyzed the clinical characteristics of these cases and provided references for the safe clinical use of carbapenems. Individual cases of platelet abnormalities caused by the carbapenem drugs, including imipenem and meropenem, were collected from PubMed, Medline, the Chinese Academic Journal Full-text Database (CNKI), and the Vip Chinese Science and Technology Journal Database. The patients’ conditions (such as sex and age), diseases, and prognoses were statistically analyzed. Three cases of platelet abnormalities were observed after the clinical use of imipenem, and 17 cases were reviewed for meropenem. Among these cases, carbapenem caused 11 cases of platelet elevation and 9 cases of thrombocytopenia. The ADRs were resolved within 4–18 d after drug withdrawal and were classified as serious adverse drug reactions. Although there are limited reports of ADRs caused by carbapenems resulting in platelet abnormalities, the consequences can be serious. Therefore, in clinical practice, special attention should be given to the ADRs of carbapenems in blood, early monitoring, and timely symptomatic treatment.

Key words: Carbapenem, Thrombocytopenia, Adverse drug reactions, Literature analysis

Supporting:

常馨予, 韩丽娟, 刘洋, 范峥, 吴剑坤. 碳青霉烯类药物致血小板不良反应分析及相关文献回顾[J]. 中国药学(英文版), 2023, 32(10): 835-841.

Xinyu Chang, Lijuan Han, Yang Liu, Zheng Fan, Jiankun Wu. Analysis of adverse drug reactions caused by carbapenems and review of related literature[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(10): 835-841.

图/表 4

参考文献 31

[1]	Yan, Q.; Xia, P.Y.; Yang, F.; Lv, X.J. Clinical Pharmacotherapy·Infectious diseases. People’s Health Publishing House. 2017.
[2]	Wang, G.F.; Li, J.; Lu, J.M.; Wang, Y.; Li, Z.P. Adverse drug reactions caused by carbapenems. Eval. Anal. Drug Use Hosp. China. 2017, 6, 830–835.
[3]	Tang, C.M.; Yang, S.Y.; Zhan, Y.Y.; Chen, L. Research on adverse reaction signal mining of three carbapenems based on FAERS database. Cent. South Pharm. 2021, 19, 2576–2581.
[4]	Li, J.T.; Li, B.; Liu, X.H. Treatment analysis and literature review of a patient with thrombocytosis secondary to pulmonary abscess. Strait Pharm. J. 2019, 9, 244–246.
[5]	Li, H.X.; Dai, X.L.; Chen, X.L; Zhou, T.R. One case of meropenem-induced thrombocytopenia. Shanghai Med. Pharm. J. 2017, 23, 52–54.
[6]	Wang, Y.T.; Zhang, H.H.; Jiang, D.L.; Qi, B. Analysis of a case of thrombocytopenia. Chin. J. Lab. Diagn. 2017, 9, 1651–1652.
[7]	Wu, H.Y.; Gao, X.; Hong, X.D.; Chen, J. Clinical Pharmacist’s Pharmaceutical Intervention to A Case of Severe Thrombocytosis Caused by Meropenem in An Infant. Pharm. Today. 2015, 10, 721–723.
[8]	Ren, C.; Chen, X.; Yang, M.M.; Zhang, Y. Pharmaceutical care of ameropenem-induced thrombocytopenia patient. North. Pharm. J. 2017, 3, 370–372.
[9]	Wang, Q.; Wang, X.; Chen, X.M.; Zhang, H.F. A case report of secondary thrombocytosis caused by meropenem. Lab. Med. 2021, 1, 117–118.
[10]	Lin, H.; Li, J.L.; Wang, L. A case of thrombocytopenia caused by meropenem. China Pharm. 2008, 5, 25.
[11]	Hu, D.; Deng, A.P. Two cases of increased platelets induced by meropenem. Chin. J. Drug Appl. Monit. 2017, 2, 126–128.
[12]	Wu, Y.; Xiao, M.S. A case of severe thrombocytopenia caused by meropenem. Exp. Lab. Med. 2015, 3, 388–389.
[13]	Gan, H.Z.; Chen, Q.H.; Chen, D.Z.; Xu, Y.Y.; Wang, J.K. A case of extreme thrombocytosis caused by meropenem injection. Chin. J. Pharm. 2021, 11, 780–781.
[14]	Huang, B.K.; Li, S.P.; Wang, X.Y. A case of thrombocytopenia caused by meropenem injection. J. Pract. Gynecol. Endocrinol. 2018, 19, 181–184.
[15]	Li, Y.Y.; Zhu, Y.B. A case of thrombocytopenia caused by meropenem injection. Chin. J. Pharm. 2017, 8, 505–506.
[16]	Liu, Y.R.; He, Y.J. Thrombocytosis caused by meropenem for injection. Adv. Drug React. J. 2021, 10, 544–545.
[17]	Kashif, H.; Muhammad, S.S.; Naureen, M.; Ambreen, M.; Sidra, I. Meropenem-induced pancytopenia in a preterm neonate: a case report. J. Med. Case Reports. 2021, 15, 25.
[18]	Cachia, J.; Torpiano, P.; Pace, D. Meropenem-induced thrombocytopenia: a paediatric case. BMJ Case Rep. 2021, 14, e243443.
[19]	Huang, T.; Zhang, J.; Liu, Y.; Cao, Z.; Shi, X.K. A case of thrombocytosis induced by imipenem cilastatin sodium. Cent. South Pharm. 2019, 10, 1803–1804.
[20]	Yu, Y.C.; Gao, D.Q. Severe thrombocytopenia induced by imipenem and cilastatin sodium. Adv. Drug React. J. 2020, 11, 654–655.
[21]	Xu, J. Analysis of adverse reactions of imipenem cilastatin sodium in two cases. Med. Pharm. J. Chin. PLA. 2011, 1, 60–61.
[22]	Sun, X. Analysis of common adverse drug reactions and rational drug use in the elderly. J. Clin. Ration. Drug Use. 2017, 29, 89–90.
[23]	Wang, Z.Y.; Zhu, H.C. Study on Common Adverse Drug Reaction Reports and Rational Drug Use Intervention Measures in the Elderly. Gansu Sci. Technol. 2020, 16, 134–136.
[24]	Chen, H. Analysis of Adverse Drug Reactions and Rational Drug Use Interventions in the Elderly. China Health Nutr. 2016, 25, 318–319.
[25]	Du, L.P.; Mei, D. Pathogenesis, clinical manifestations, prevention and treatment of drug-induced thrombocytopenia. Adv. Drug React. J. 2007, 6, 414–419.
[26]	Qin, W.; Wang, X.X.; Du, W.W.; Cui, G. Research progress in drug-induced thrombocytopenia. Eval. Anal. Drug Use Hosp. China. 2017, 5, 578–579.
[27]	Yang, J.Y.; Gu, J. Research progress in the mechanism of drug-induced thrombocytopenia. Chin. J. Hosp. Pharm. 2013, 22, 1874–1877.
[28]	Zhao, X.Z.; Cui, H.G. Research progress in the classification of drug-induced immune thrombocytopenia and the diagnosis and treatment of tirofiban induced thrombocytopenia. Shandong Med. J. 2022, 33, 102–106.
[29]	Chen, C.C.; Tan, R.J.; Wang, L.S.; Zhang, Y.Y.; Hu, X.Y.; Chen, Y.Y. Clinical characteristics and risk factors of thrombocytopenia induced by fluoroquinolones. Chin. J. Pharm. 2022, 3, 306–309.
[30]	Chen, S.Y.; Li, X.; Liu, L.H.; He, X.; Ma, H.L.; Zhang, M.M. Literature analysis of drug-induced secondary thrombocytosis, Literature Analysis on Drug-induced Second Thrombocytosis. China Pharm. 2017, 9, 1633–1635.
[31]	Pei, Y.Y.; Hao, J.H.; Duan, W.Q.; Zheng, Y.J.; Zhao, M.; Yang, L.P. Severe and lethal adverse reactions of linezolid—a summary analysis of case reports. J. Chin. Pharm. Sci. 2022, 31, 153–161.

碳青霉烯类药物致血小板不良反应分析及相关文献回顾

Analysis of adverse drug reactions caused by carbapenems and review of related literature

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 4

参考文献 31

相关文章 3

编辑推荐

Metrics

本文评价

[1]	杨晗春, 成斐, 黄娟娟. 艾曲波帕对难治性原发免疫性血小板减少症的疗效及其对细胞免疫功能的影响[J]. 中国药学(英文版), 2023, 32(9): 736-743.
[2]	袁叶, 于博, 杨珍珍, 董维冲, 杨秀岭. 达格列净在血容量不足患者中的药学监护及文献分析[J]. 中国药学(英文版), 2022, 31(9): 718-722.
[3]	武海艳, 王涛, 王倩, 唐琳. 新生儿无乳链球菌脑膜炎的抗感染治疗方案分析及停药指征探讨[J]. 中国药学(英文版), 2021, 30(8): 686-691.